Updating targets for natural killer/T-cell lymphoma immunotherapy

Xue, Weili; Zhang, Mingzhi

doi:10.20892/j.issn.2095-3941.2020.0400

Cited by 14 publications

(15 citation statements)

References 99 publications

(49 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We will not discuss these in details, but excellent reviews, such as those from Nebrinsky and co-workers, Chung et al, Klener and Klanova, or Othman and co-workers are suggested in this topic for those interested [370,381,384,385]. In addition, therapeutic challenges for NK/T-cell lymphomas are discussed in articles, such as the ones from Xue and Zhang, or Wang and co-workers [386,387]. nHLs and mitochondria.…”

Section: Non-hodgkin Lymphomas (Nhls)mentioning

confidence: 99%

Mitochondria and Their Relationship with Common Genetic Abnormalities in Hematologic Malignancies

Czegle

Gray

Wang³

et al. 2021

Life

View full text Add to dashboard Cite

Hematologic malignancies are known to be associated with numerous cytogenetic and molecular genetic changes. In addition to morphology, immunophenotype, cytochemistry and clinical characteristics, these genetic alterations are typically required to diagnose myeloid, lymphoid, and plasma cell neoplasms. According to the current World Health Organization (WHO) Classification of Tumors of Hematopoietic and Lymphoid Tissues, numerous genetic changes are highlighted, often defining a distinct subtype of a disease, or providing prognostic information. This review highlights how these molecular changes can alter mitochondrial bioenergetics, cell death pathways, mitochondrial dynamics and potentially be related to mitochondrial genetic changes. A better understanding of these processes emphasizes potential novel therapies.

show abstract

Section: Non-hodgkin Lymphomas (Nhls)mentioning

confidence: 99%

Mitochondria and Their Relationship with Common Genetic Abnormalities in Hematologic Malignancies

Czegle

Gray

Wang³

et al. 2021

Life

View full text Add to dashboard Cite

show abstract

“…Conclusively, the induction response might be used for better risk stratification and the induction response-adapted individualized strategy might be of potential value in decision-making in NKTCL. Actually, apart from increased drug dosage which have been discussed above, combination of CRT with new anticancer agents including immune checkpoint inhibitors, epigenetic drugs, adaptive immune therapy and other agents might also be of potential value to decrease SF and prolong survivals for localized NKTCL, some of which are under investigation currently [9,[44][45][46][47].…”

Section: Discussionmentioning

confidence: 99%

Deep remission from induction chemotherapy predicts favorable long-term survivals in early stage extranodal nasal NK/T-cell lymphoma receiving sequential chemotherapy and radiation

Zhou

Xie

et al. 2022

Aging

View full text Add to dashboard Cite

Objective: We aimed to assess the association between induction chemotherapy (CT) response and survivals and to explore an induction CT response-adapted treatment strategy for localized extranodal NK/T-cell lymphoma (NKTCL) receiving first-line sequential CT and radiation (RT). Methods: We retrospectively reviewed the data of patients with localized NKTCL receiving first-line CT+RT from 2010 to 2020 at two independent institutes (primary cohort, n = 203; validation cohort, n = 67). Responses after induction CT (initial response), RT (final response) and survivals were analyzed. Results: Patients with initial complete remission (CR) had higher final CR rate than the others (99.1% vs. 78.7%, P < 0.001). Initial CR was associated with superior 5-year progression-free survival (PFS, 90.0% vs. 61.4% vs. 30.8%, P < 0.001) and overall survival (OS, 93.5% vs. 70.7% vs. 60.6%, P < 0.001), as compared to initial partial remission or non-response. Though majority of cases with initial non-CR achieved final CR after RT, they still had a tendency of shortened OS compared with initial CRs (86.9% vs. 90.6%, P = 0.063). Multivariate analysis demonstrated patients with initial non-CR had higher relapse (HR = 4.748, 95% CI, 2.396-9.407, P < 0.001) and death hazard (HR = 4.296, 95% CI, 1.802-10.24, P = 0.001). Furthermore, more intensive therapy of ≥6 total cycles of CT yielded significantly superior 5-year OS for patients with initial non-CR (76.7% vs. 54.7%, P = 0.026) rather than patients with initial CR. Conclusion: Deep remission from induction CT was associated with favorable survivals in localized NKTCL receiving CT+RT, and an induction CT response-adapted individualized treatment strategy might be recommended in clinical practice.

show abstract

“…Advanced/relapsed/recurrent NKTCL are treated with selective chemotherapy but due to poor host response and drug-induced toxicity has resulted in poor patient prognosis in many of the cases. Hematopoietic stem cell transplant and immunotherapy are still under trial [ 55 ].…”

Section: Nk/t Cell Lymphoma (Nktcl)mentioning

confidence: 99%

Molecular Genetics in Epstein–Barr Virus-Associated Malignancies

Umakanthan

Bukelo

2021

Life

View full text Add to dashboard Cite

Global genomic studies have detected the role of genomic alterations in the pathogenesis of Epstein–Barr virus (EBV)-associated tumors. EBV oncoproteins cause a vital shift of EBV from an infectious virus to an oncogenic form during the latent and lytic phase within the lymphoid B cells and epithelial cells. This epigenetic alteration modulates the virus and host genomes and inactivates and disrupts numerous tumor suppressors and signaling pathways. Genomic profiling has played the main role in identifying EBV cancer pathogenesis and its related targeted therapies. This article reviews the role of genetic changes in EBV-associated lymphomas and carcinomas. This includes the prolific molecular genesis, key diagnostic tools, and target-specific drugs that have been in recent clinical use.

show abstract

Updating targets for natural killer/T-cell lymphoma immunotherapy

Cited by 14 publications

References 99 publications

Mitochondria and Their Relationship with Common Genetic Abnormalities in Hematologic Malignancies

Mitochondria and Their Relationship with Common Genetic Abnormalities in Hematologic Malignancies

Deep remission from induction chemotherapy predicts favorable long-term survivals in early stage extranodal nasal NK/T-cell lymphoma receiving sequential chemotherapy and radiation

Molecular Genetics in Epstein–Barr Virus-Associated Malignancies

Contact Info

Product

Resources

About